Heartflow, Inc. HTFL
- Market cap
- $4.2B
- P/E
- 0.0×
Follow HTFL
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 25.38 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 41.22 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 699 | 843 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 87 | 126 | 176 |
Revenue
|
|||
| — | — | — | — | — | — | — | 66.59% | 75.07% | 76.80% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (95) | (96) | (117) |
EBT
|
|||
| — | — | — | — | — | — | — | (109.10%) | (76.60%) | (66.39%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (96) | (96) | (117) |
Net Income
|
|||
| — | — | — | — | — | — | — | 10 | 10 | 12 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 17.84 | 23.46 | 4.78 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (19.58) | (17.98) | (3.17) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (15.65) | (12.87) | (1.47) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (1.25) | (0.81) | (0.14) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (16.90) | (13.68) | (1.60) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (1.84) | (16.95) | 8.16 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 5 | 5 | 37 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 1.28 | 1.28 | 6.10 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 3.57 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 1.96 | 1.96 | 6.13 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (4.29) | (4.29) | (18.29) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | (76) | (69) | (54) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (6) | (4) | (5) |
Capex
|
|||
| — | — | — | — | — | — | — | (83) | (73) | (59) |
FCF
|
|||
| — | — | — | — | — | — | — | 116 | 49 | 178 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 134 | 136 | — |
Total Debt
|
|||
| — | — | — | — | — | — | — | 11 | 85 | (177) |
Net Debt
|
|||
| — | — | — | — | — | — | — | (9) | (91) | 301 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (63.49%) | (48.85%) |
ROA
|
|||
| — | — | — | — | — | — | — | (2,031.71%) | 0.00% | (32.33%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 11.78% | 41.80% |
ROE
|
|||
Heartflow, Inc. peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DOCS Doximity, Inc. | $4.6B | 29.6× | Compare |
| WAY Waystar Holding Corp. | $4.7B | 34.3× | Compare |
| PRVA Privia Health Group, Inc. | $2.5B | 89.6× | Compare |
| HQY HealthEquity, Inc. | $7.3B | 31.6× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HNGE Hinge Health Inc. | $7.4B | 70.8× | Compare |
| SDGR Schrodinger, Inc. | $2.2B | 0.0× | Compare |
| TXG 10x Genomics | $11.1B | 0.0× | Compare |
| BTSG BrightSpring Health Services, Inc. | $11.1B | 31.6× | Compare |
Heartflow, Inc. (HTFL) key facts
- Heartflow, Inc. (HTFL) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- Heartflow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $176.0 million, up 39.9% from fiscal 2024.
- As of September 25, 2026, HTFL traded at $49.17, a market capitalization of $4.2 billion.
- Return on equity was 41.8% and debt-to-equity 0.00.
Heartflow, Inc. (HTFL) Latest News
28 Aug
Late-breaking data from an independent government-funded trial at ESC shows Heartflow FFRCT analysis reduces unnecessary invasive heart procedures by nearly half. Positive trial results highlight FFRCT effectiveness in halving unnecessary procedures, likely accelerating clinical adoption and revenue growth.
16 Aug
HTFL shares surge 46%. Analysts issue opinions on the move while hedge funds adjust positions in the stock. 46% price surge reflects major market momentum that can shift investor sentiment and valuation trajectory.
HeartFlow beats Q2 expectations and raises guidance, resulting in a fair value boost for HTFL stock. Q2 earnings beat and raised guidance drive higher fair value for the company.
HeartFlow (HTFL) shares rose after Q2 results and an increased company outlook, though the stock is viewed as fully valued at current levels. Q2 results and raised outlook signal stronger near-term financial performance without fundamentally shifting long-term valuation or competitive position.
14 Aug
Heartflow stock soared on strong investor reaction to positive developments boosting near-term outlook. Stock surge signals major positive shift likely to lift future performance and sentiment.
Heartflow, Inc. (HTFL) stock broke out after an outsized guidance boost linked to its AI technology post-IPO. Outsized guidance boost triggered stock breakout and signals major positive shift in HTFL trajectory.
HeartFlow Inc (HTFL) Q2 2026 revenue surged 48% with continued plaque momentum. 48% revenue surge in Q2 2026 points to major positive shift in financial trajectory and investor sentiment.
Heartflow, Inc. released its Q2 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Quarterly earnings data and guidance influence near-term investor views and valuation without guaranteeing major strategic shifts.
13 Aug
Heartflow reported second quarter 2026 financial results and raised full year 2026 guidance. Quarterly results release paired with raised guidance signals stronger expected performance likely to shift investor sentiment and valuation.
Heartflow Q2 earnings call highlights revenue growth, increased adoption of its AI coronary diagnostics, and positive forward guidance on market expansion. Q2 earnings and guidance supply financial and strategic updates that moderately shift near-term investor views and operational outlook.
HeartFlow reported a Q2 loss while beating revenue estimates. Q2 loss offset by revenue beat creates moderate short-term effects on financial perception and stock movement.
9 Jul
New data at SCCT 2026 reinforce Heartflow Plaque Analysis as the standard for AI-powered coronary artery disease management. Conference data validating Heartflow's AI plaque analysis as clinical standard boosts product adoption and competitive edge.
15 May
HeartFlow Inc. (HTFL) reported robust revenue growth in Q1 2026 earnings call, raised full-year guidance, highlighted strong adoption of AI-powered heart disease platform, and expanded commercial team amid expanding market opportunities. Robust revenue growth and raised guidance represent major positive shifts in financial performance and market positioning for HeartFlow.
14 May
HeartFlow, Inc. (HTFL) released Q1 earnings call highlights detailing financial results, operational updates, and forward guidance. Q1 earnings call highlights disclose financial performance and strategic developments poised to significantly influence HTFL's market trajectory and investor sentiment.
Heartflow, Inc. (HTFL) reported first quarter 2026 financial results and raised full-year 2026 guidance. Raising full-year guidance post-Q1 results signals strong financial momentum with significant potential to enhance market performance and investor sentiment.
8 May
Heartflow (HTFL) merits portfolio consideration due to its pioneering AI-powered FFRct platform for noninvasive coronary artery disease diagnosis, robust revenue growth exceeding 30% YoY, expanding Medicare coverage, key partnerships with Siemens and Philips, and promising clinical trial results, though high valuation, competition from traditional methods, and regulatory risks pose challenges. Heartflow's revenue growth and Medicare expansion signal moderately noticeable positive influence on financial performance and market positioning.
13 Apr
Heartflow Inc. (HTFL) files patent infringement lawsuit against competitor Cleerly. Patent infringement lawsuit against Cleerly targets competitive positioning in cardiovascular diagnostics without guaranteed outcome.
23 Mar
Heartflow Inc. (HTFL) shares soared 27% as the company targets double-digit growth. A 27% stock surge on double-digit growth targets signals major positive shifts in investor sentiment and company trajectory.
22 Mar
Capricorn Investment Group bought 1.7 million shares of HeartFlow Inc. (HTFL), prompting questions on whether the stock represents a buy opportunity. Capricorn Investment Group's purchase of 1.7 million shares signals confidence and may moderately boost market sentiment without fundamentally changing HeartFlow's trajectory.
18 Mar
HeartFlow Inc. (HTFL) reported record revenue growth in Q4 2025 earnings call, alongside strategic initiatives driving future expansion. Record revenue growth and strategic advancements position HTFL for significant enhancements in market performance and competitive standing.
Heartflow, Inc. (HTFL) Q4 earnings call highlights key financial results, operational achievements, and forward guidance. Q4 earnings call highlights signal significant financial performance and strategic shifts influencing HTFL's market trajectory.
HeartFlow reported Q4 revenue of $75.4 million, up 52% year-over-year, with full-year revenue hitting $224 million, a 79% increase. The company posted positive cash flow from operations of $11.5 million for the first time and narrowed its net loss to $102.3 million. Record revenue growth and inaugural positive operating cash flow demonstrate strong financial momentum and scalability, significantly boosting future performance prospects.
Heartflow, Inc. (HTFL) reported fourth quarter and full-year 2025 financial results. Quarterly and annual financial results disclosure significantly affects investor sentiment, stock valuation, and future performance expectations for HTFL.
Heartflow, Inc. (HTFL) leverages AI in its non-invasive fractional flow reserve (FFRct) technology for coronary artery disease diagnosis, positioning it as a prime beneficiary amid the AI-driven healthcare revolution, with strong revenue growth and expanding clinical adoption. AI advancements directly enhance Heartflow's core diagnostic platform, driving significant revenue growth and competitive positioning in cardiology.
17 Mar
HeartFlow Inc. (HTFL) reported Q4 2025 earnings results, highlighted as earnings to watch. Q4 earnings reports typically drive significant shifts in stock price, investor sentiment, and future performance expectations for HTFL.
16 Mar
Heartflow Inc. (HTFL) expands clinical evidence across heart disease care continuum, from precision risk stratification to CT-guided intervention planning. Building comprehensive evidence base across heart disease continuum strengthens Heartflow's product validation, adoption potential, and market positioning.
25 Feb
Heartflow, Inc. (HTFL) announces expansion of its GAMEFILM Registry to advance clinical evidence for its AI-powered heart disease analysis platform. Registry expansion bolsters clinical data for regulatory validation and market adoption without fundamentally altering competitive positioning.
23 Feb
HeartFlow expands GAMEFILM platform, integrating athlete heart data with AI to drive valuation narrative and open new markets in sports cardiology. GAMEFILM expansion into athlete heart data with AI represents a major strategic pivot enhancing competitive positioning and investor valuation prospects.
12 Feb
Heartflow, Inc. has expanded its GAMEFILM Registry to include NBA and NHL alumni, aiming to accurately assess heart disease risk among former professional athletes. This initiative enhances the company's focus on cardiovascular health and leverages its advanced imaging technology to provide personalized insights into heart conditions. The expansion of the GAMEFILM Registry to professional athletes represents a significant strategic move that could enhance Heartflow's market position and investor sentiment.
10 Jan
HeartFlow, Inc. (HTFL) has experienced notable share price momentum, raising questions about its valuation, particularly given its high price-to-sales multiple. Analysts are assessing whether the recent price increases are justified based on the company's financial performance and market position. The article highlights the need for investors to consider the sustainability of this momentum in light of the company's fundamentals. Recent share price momentum may influence investor sentiment and financial performance but is not expected to fundamentally alter the company's trajectory.